Telomeres

Two problems and one solution

Linear DNA presents the cell with two awkward problems that circular bacterial chromosomes do not have. The first is the end-replication problem. DNA polymerase needs an RNA primer and synthesises only 5'-to-3', so on the lagging strand the very last primer cannot be replaced once removed; a few dozen nucleotides at every chromosome tip are lost at every replication. Without an end-protection mechanism every chromosome would erode from its tip outward generation by generation. The second is the end-protection problem. A free double-stranded DNA end looks identical to a double-strand break, and the cell's NHEJ machinery would try to fuse it to whatever else is nearby, scrambling the karyotype within a few divisions.

Telomeres solve both problems at once. The repeats provide an expendable buffer for the end-replication problem — eroding tens of base pairs of TTAGGG harms nothing — and the shelterin-bound t-loop hides the end from the damage machinery. They also serve a third purpose: by shortening predictably with every division, they implement a built-in division counter that limits how many times any somatic cell can replicate.

Structure: repeat, overhang, t-loop, shelterin

A vertebrate telomere is a tract of 5'-TTAGGG-3' on one strand and the complementary 5'-CCCTAA-3' on the other, repeated thousands of times. The 3' end of the G-rich strand extends 50-300 nucleotides past the C-rich strand to form a single-stranded G-overhang. That overhang folds back into the upstream double-stranded telomere, invades it, and base-pairs with the C-rich strand, producing a lariat-shaped t-loop with a smaller D-loop at the invasion site. The 3' end is therefore tucked safely inside, not free.

Six proteins constitute shelterin and bind the telomere as a stoichiometric complex. TRF1 and TRF2 each home in on double-stranded TTAGGG repeats; POT1 binds the single-stranded overhang; TIN2 bridges TRF1, TRF2, and TPP1; TPP1 docks POT1 to the rest of the complex; and RAP1 binds TRF2. TRF2 is the keystone — losing it dissolves the t-loop in minutes and chromosome ends start fusing immediately. POT1 is the keystone for the overhang side; losing it triggers ATR signalling. The whole complex is thought to occupy a few hundred shelterin units along an average human telomere.

Telomere length and repeat across species

Species	Repeat sequence	Typical length (kb)	Telomerase activity in soma	Notes
Human	5'-TTAGGG-3'	10-15	Off in most cells; on in stem cells and germline	Shortens 50-200 bp per division; Hayflick limit ~50 doublings
Mouse	5'-TTAGGG-3'	30-150	Active in many somatic tissues	Long telomeres mask phenotypes; need late-generation knockouts to see effects
Budding yeast (S. cerevisiae)	5'-TG(1-3)-3' (irregular)	0.3 (~300 bp)	Constitutive (Est2 telomerase)	Short, dynamic; senesces if telomerase is deleted (~75 generations)
Tetrahymena thermophila	5'-TTGGGG-3'	~0.4	Constitutive	Where telomerase was discovered (Greider & Blackburn, 1985); Nobel 2009
Arabidopsis thaliana	5'-TTTAGGG-3'	2-5	Active	Plant telomeres survive deletion of telomerase for ~10 generations
Trypanosoma brucei	5'-TTAGGG-3'	3-15	Active	VSG antigenic-variation cassette is inside the telomere

The numbers reveal a few things. First, the TTAGGG repeat is conserved across all vertebrates and many distant eukaryotes — it is one of the oldest sequences in biology. Second, mouse telomeres are dramatically longer than human telomeres, which is why telomerase-knockout mice show phenotypes only after several generations of breeding (G4-G6 mice are the standard model). Third, ciliates like Tetrahymena have so many tiny chromosomes (and therefore so many telomeres) that they are the ideal place to study the enzyme — Carol Greider and Elizabeth Blackburn purified telomerase from Tetrahymena extract in 1985 and won the 2009 Nobel Prize.

Telomerase: a reverse transcriptase that brings its own template

Telomerase is a ribonucleoprotein with two essential subunits and several accessory ones. The catalytic subunit TERT is a reverse transcriptase distantly related to retroviral RT — it has fingers, palm, and thumb subdomains and a primer grip. The RNA component TERC (in humans 451 nt; in Tetrahymena just 159 nt) is the template: about 11 nucleotides of TERC read 5'-CUAACCCUAAC-3', complementary to one and a half TTAGGG repeats. TERT positions the 3' end of the telomere over the templating region, copies a few nucleotides of new DNA, then translocates — the newly added DNA repositions on the RNA template and the next repeat begins. The enzyme is processive: many repeats can be added per binding event in vertebrates, while in yeast it tends to add only one.

The catalytic core is supported by dyskerin (DKC1) and the H/ACA RNP machinery, which bind the 3' end of TERC and stabilise the RNA. Mutations in DKC1, TERT, or TERC are the cause of dyskeratosis congenita and adult-onset telomere biology disorders — patients run out of stem-cell self-renewal early, presenting with bone-marrow failure, lung fibrosis, and increased cancer risk.

Telomeres vs other chromosome strategies

	Vertebrate telomere	Drosophila telomere	Bacterial chromosome
Repeat sequence	5'-TTAGGG-3'	Het-A and TART retrotransposons	None — circular DNA
Maintenance	Telomerase or ALT	Targeted retrotransposition	Topoisomerase decatenation
End-protection complex	Shelterin (six proteins)	HOAP / HipHop complex	Not applicable
End-replication problem	Yes — solved by telomerase	Yes — solved by transposon insertion	No — chromosome is circular
Hayflick-style attrition	Yes	Different mechanism	No

Drosophila is the famous outlier: it gave up telomerase entirely and uses targeted retrotransposition of two specialised elements (Het-A and TART) to extend its chromosome ends. The strategy works because flies do not rely on TTAGGG repeats and can absorb retrotransposon insertions at the tip without disrupting genes. The fly story is a useful reminder that telomerase is not the only way to maintain a linear chromosome.

Where telomere biology shows up

• Cancer. Roughly 90% of cancers reactivate telomerase. Activating point mutations in the TERT promoter (-124 C>T and -146 C>T, mutually exclusive) appear in 70-80% of melanomas, glioblastomas, hepatocellular carcinomas, and bladder cancers. The remaining 10% of tumours use ALT (alternative lengthening of telomeres), a homologous-recombination pathway. Telomerase inhibitors (imetelstat) are in clinical trials for myelofibrosis and myelodysplastic syndromes.
• Telomere biology disorders. Dyskeratosis congenita, idiopathic pulmonary fibrosis, and aplastic anaemia together affect millions globally. Roughly 10% of adult IPF cases carry telomere-shortening mutations.
• Hayflick limit and senescence. Cultured human fibroblasts stop dividing after 40-60 doublings; introducing TERT (Bodnar et al., 1998) immortalises them indefinitely. The same mechanism is what limits stem-cell-based regenerative therapies and what made HeLa cells a famous exception.
• Aging biomarkers. Leukocyte telomere length correlates weakly with chronological age and more strongly with cumulative oxidative stress; epigenetic clocks based on DNA methylation predict age more accurately than telomere length alone.
• Cloning and IVF. Dolly the sheep had short telomeres at birth, inherited from her donor cell. Reprogramming somatic cells to iPSCs partially resets telomere length, but the field still debates how complete the reset is.

Variants of the maintenance strategy

• Telomerase-positive cells. Stem cells, germline, activated lymphocytes, and most cancers maintain telomeres through TERT/TERC.
• ALT (alternative lengthening of telomeres). Uses homologous recombination to copy repeats from sister or non-sister telomeres. Common in osteosarcoma and pediatric brain tumours; often associated with mutations in ATRX and DAXX.
• Drosophila retrotransposition. Two LINE-like elements (Het-A and TART) target chromosome ends and extend them by reverse transcription, replacing the role of telomerase entirely.
• Pavlovian regulation. Some yeast use multiple telomerase paralogues with different processivities (Est2 for routine maintenance, Stn1/Ten1 for capping); fission yeast separates Taz1 (TRF homologue) from POT1 differently than vertebrates.
• G-quadruplex stabilisers. Drugs like telomestatin force the G-rich overhang into a four-stranded G-quadruplex structure that telomerase cannot extend; a clinical strategy distinct from direct enzyme inhibition.

Pitfalls and easy misreadings

• "Telomeres are the cause of ageing." Telomere shortening contributes to replicative senescence in cells that divide a lot, but most ageing tissues (neurons, cardiomyocytes) divide rarely and have minimal telomere shortening. Ageing is multifactorial; telomere biology is one of nine canonical hallmarks, not the master switch.
• "More telomerase is good." Telomerase reactivation is a step toward immortality but also toward cancer — over 90% of human tumours rely on it. Mice engineered to over-express TERT live a few months longer but with elevated tumour rates unless tumour suppressors are also boosted.
• "Lifestyle changes lengthen telomeres." Studies of meditation, diet, and exercise report tiny effect sizes (a few hundred base pairs) and rarely replicate. The biology of measured "lengthening" is often telomere fragment exchange rather than de novo addition.
• "Mouse telomeres model human telomeres." Mouse telomeres are 5-15× longer than human telomeres and most somatic tissues retain telomerase activity, so wild-type mice show no Hayflick limit. Late-generation TERT-knockout mice are required to see human-like phenotypes.
• "Checkpoint failure equals cancer." Critically short telomeres do drive crisis and karyotype scrambling, but the resulting mutator phenotype is also frequently lethal — most pre-cancer crisis cells die. Only the rare survivor that reactivates telomerase emerges as a tumour.